Daniel T Laskowitz

US Patent:

7319092, Jan 15, 2008

Filed:

Mar 29, 2005

Appl. No.:

11/091336

Inventors:

Daniel T. Laskowitz - Chapel Hill NC, US
William D. Matthew - Durham NC, US
Michael McMillian - Rareton NJ, US

Assignee:

Cognosci, Inc - Research Triangle Park NC

International Classification:

A61K 38/00

US Classification:

514 13, 514 2, 514 21, 530300, 530326

Abstract:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

US Patent:

7592141, Sep 22, 2009

Filed:

Dec 13, 2005

Appl. No.:

11/302064

Inventors:

Debra A. Schwinn - Durham NC, US
Daniel Laskowitz - Chapel Hill NC, US
Mihai V. Podgoreanu - Raleigh NC, US
Eugene W. Moretti - Durham NC, US

Assignee:

Duke University - Durham NC

International Classification:

C12Q 1/68
C12P 19/34
C12M 1/34
C07H 21/04

US Classification:

435 6, 435 911, 435 912, 4352871, 536 2431, 536 2433

Abstract:

The present invention provides a method of identifying a subject having a reduced risk of developing sepsis, comprising detecting at least one APOE3 allele in nucleic acid from the subject.

US Patent:

7915226, Mar 29, 2011

Filed:

Aug 27, 2007

Appl. No.:

11/845463

Inventors:

Daniel T. Laskowitz - Chapel Hill NC, US
William D. Matthew - Durham NC, US
Michael McMillian - Rareton NJ, US

Assignee:

Cognosci, Inc. - Research Triangle Park NC

International Classification:

A61K 38/00

US Classification:

514 214, 530324, 530326, 514 177, 514 213

Abstract:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

US Patent:

8034762, Oct 11, 2011

Filed:

Jan 31, 2008

Appl. No.:

12/023288

Inventors:

Michael P. Vitek - Cary NC, US
Daniel T. Laskowitz - Chapel Hill NC, US

Assignee:

Cognosci, Inc. - Research Triangle Park NC

International Classification:

A61K 38/00
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00

US Classification:

514 11, 530324, 530325, 530326

Abstract:

Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.

US Patent:

8093209, Jan 10, 2012

Filed:

Dec 4, 2008

Appl. No.:

12/328625

Inventors:

Daniel T. Laskowitz - Chapel Hill NC, US
William D. Matthew - Durham NC, US
Michael McMillian - Rareton NJ, US

Assignee:

Cognosci, Incorporated - Research Triangle Park NC

International Classification:

A61K 38/16
A61P 31/00

US Classification:

514 14, 530324, 530326

Abstract:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. ApoE receptor binding peptides that may be used in the methods of the invention are also described, as are methods of using such peptides to treat peripheral inflammatory conditions such as sepsis. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

US Patent:

8198234, Jun 12, 2012

Filed:

May 13, 2010

Appl. No.:

12/779725

Inventors:

Daniel T. Laskowitz - Chapel Hill NC, US
William D. Matthew - Durham NC, US
Michael McMillian - Rareton NJ, US

Assignee:

Cognosci, Incorporated - Research Triangle Park NC

International Classification:

A61K 38/00

US Classification:

514 19, 514 177, 514 178, 514 179, 514 214, 514 215

Abstract:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

US Patent:

8288336, Oct 16, 2012

Filed:

Oct 10, 2011

Appl. No.:

13/270105

Inventors:

Michael P. Vitek - Cary NC, US
Daniel T. Laskowitz - Chapel Hill NC, US

Assignee:

Cognosci, Inc. - Research Triangle Park NC

International Classification:

A61K 38/00
A61K 38/04
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00

US Classification:

514 11, 530324, 530325, 530326

Abstract:

Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.

US Patent:

20020164789, Nov 7, 2002

Filed:

Sep 21, 2001

Appl. No.:

09/957909

Inventors:

Daniel Laskowitz - Chapel Hill NC, US
William Matthew - Durham NC, US
Michael McMillian - Rareton NJ, US

International Classification:

A61K038/17
C12Q001/70
A61K038/00
A61K031/70
A01N043/04
C12N005/06
C12N005/16

US Classification:

435/343000, 514/012000, 514/044000, 435/005000

Abstract:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.